Compare Amplify Cybersecurity ETF (HACK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Organon & Co. Common Stock — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Amplify Cybersecurity ETF and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Organon & Co. Common Stock for 0 Days on average.
| HACK | OGN | |
|---|---|---|
Market Cap | $3.56B | $3.62B |
Volume | 331,197 | 2,892,999 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $13.81 |
52-Week Low | $70.69 | $5.70 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.
The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
